Condition

Deleterious PALB2 Gene Mutation

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions7

Lead sponsors shown2

Clinical trials

2 shown

Niraparib + Dostarlimab In BRCA Mutated Breast CancerNCT04584255 · 2021-01-21

ACTIVE_NOT_RECRUITING

Surgery in Preventing Ovarian Cancer in Patients With Genetic MutationsNCT02760849 · 2016-05-02

ACTIVE_NOT_RECRUITING

Common interventions

DostarlimabDRUG1Laboratory Biomarker AnalysisOTHER1NiraparibDRUG1OophorectomyPROCEDURE1Quality-of-Life AssessmentOTHER1SalpingectomyPROCEDURE1Salpingo-OophorectomyPROCEDURE1

Leading sponsors

Dana-Farber Cancer Institute1M.D. Anderson Cancer Center1

Trial status mix

ACTIVE_NOT_RECRUITING2

Phase mix

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.